Home > Insider Trading > Filing (0000874015-13-000116)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
874015	Isis Pharmaceuticals Inc	ISIS	Pharmaceutical Preparations (2834)	330336973

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1073384	H Joseph Wender	C/O Isis Pharmaceuticals, Inc. 2855 Gazelle Court Carlsbad CA 92010		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2013-12-19	15,000	$16.32	60,866	No	4	M	Direct
Common Stock	Disposition	2013-12-19	9,731	$39.13	51,135	No	4	S	Direct
Common Stock	Disposition	2013-12-20	10,000	$40.01	41,135	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Director Stock Option (right to buy)	Disposition	2013-12-19	15,000	$0.00	15,000	$16.32

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2013-07-01	2019-06-30	No	4	M	Direct

Footnotes

The shares were sold to cover the cost of the option exercise price and estimated taxes due.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.00 to $39.29, inclusive. The reporting person undertakes to provide to Isis Pharmaceuticals, Inc., any security holder of Isis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.04, inclusive. The reporting person undertakes to provide to Isis Pharmaceuticals, Inc., any security holder of Isis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.